Thermo Fisher Scientific Inc (TMO): Price and Financial Metrics
Thermo Fisher Scientific Inc (TMO)
Today's Latest Price: $365.89 USD
Updated Jul 2 7:00pm
Add TMO to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 58 in Medical - Diagnostics/Research
See all "A" rated Strong Buy stocks
TMO Stock Summary
- With a market capitalization of $143,106,583,023, Thermo Fisher Scientific Inc has a greater market value than 98.97% of US stocks.
- TMO's went public 32.85 years ago, making it older than 91.61% of listed US stocks we're tracking.
- In terms of volatility of its share price, TMO is more volatile than only 2.8% of stocks we're observing.
- Stocks with similar financial metrics, market capitalization, and price volatility to Thermo Fisher Scientific Inc are NVO, NKE, TMUS, DHR, and ABT.
- TMO's SEC filings can be seen here. And to visit Thermo Fisher Scientific Inc's official web site, go to www.thermofisher.com.
TMO Stock Price Chart Technical Analysis Charts
TMO Price/Volume Stats
| Current price | $365.89 | 52-week high | $369.82 |
| Prev. close | $359.77 | 52-week low | $250.21 |
| Day low | $362.00 | Volume | 1,127,751 |
| Day high | $369.82 | Avg. volume | 1,895,976 |
| 50-day MA | $343.24 | Dividend yield | 0.24% |
| 200-day MA | $317.04 | Market Cap | 144.51B |
Thermo Fisher Scientific Inc (TMO) Company Bio
Thermo Fisher Scientific provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics worldwide. The company was founded in 1956 and is based in Waltham, Massachusetts.
TMO Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $365.89 | $149.3 | -57% |
Below please find a table outlining a discounted cash flow forecast for TMO, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Thermo Fisher Scientific Inc ranked in the 28th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 57.17%. As for the metrics that stood out in our discounted cash flow analysis of Thermo Fisher Scientific Inc, consider:
- Interest coverage, a measure of earnings relative to interest payments, is 6.09; that's higher than 57.7% of US stocks in the Healthcare sector that have positive free cash flow.
- 88% of the company's capital comes from equity, which is greater than 74.78% of stocks in our cash flow based forecasting set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -58% |
| 1% | -58% |
| 2% | -57% |
| 3% | -57% |
| 4% | -57% |
| 5% | -56% |
BHC, CMD, ENTA, WAT, and ABT can be thought of as valuation peers to TMO, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...